(Q43991768)

28 November 2017

title

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C (English)

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

11 July 2024

0 references

1 reference

1 reference

Gowtham A. Rao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20833169

11 July 2024

Prashant K. Pandya

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20833169

11 July 2024

language of work or name

English

0 references

publication date

15 September 2010

1 reference

full work available at URL

28 November 2017

https://api.elsevier.com/content/article/PII:S0016508510013077?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

https://api.elsevier.com/content/article/PII:S0016508510013077?httpAccept=text/plain

11 July 2024

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

11 July 2024

1 reference

28 November 2017

volume

140

1 reference

28 November 2017

issue

1

1 reference

28 November 2017

page(s)

144-152

1 reference

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

28 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Extrahepatic manifestations of hepatitis C among United States male veterans

11 July 2024

2

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

The spectrum of extrahepatic manifestations in hepatitis C virus infection

11 July 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

11 July 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

11 July 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

11 July 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

11 July 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment

11 July 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Hepatitis C virus and type 2 diabetes

11 July 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

11 July 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection

11 July 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

11 July 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

11 July 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Predictors of response of US veterans to treatment for the hepatitis C virus

11 July 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Outcome of screening for hepatitis C virus infection based on risk factors

11 July 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source

11 July 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

11 July 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

11 July 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection

11 July 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs

11 July 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

11 July 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

11 July 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

11 July 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Efficacy of chronic hepatitis C therapy in community-based trials

11 July 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

11 July 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

11 July 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

11 July 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Replication of hepatitis C virus

11 July 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Low density lipoprotein receptor as a candidate receptor for hepatitis C virus

11 July 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

11 July 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

HCV replication and statin pleotropism: an adjuvant treatment panacea?

11 July 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

11 July 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

11 July 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Fluvastatin inhibits hepatitis C replication in humans

11 July 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

11 July 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

11 July 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

11 July 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Statins in liver disease: a molehill, an iceberg, or neither?

11 July 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

Statins and HCV: a complex issue

11 July 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.055

11 July 2024

Identifiers

1 reference

28 November 2017

1 reference